- WuXi Biologics signed an MoU with Qatar Free Zones Authority on December 2, 2025.
- The collaboration will establish WuXi's first integrated CRDMO center in the Middle East.
- The focus includes complex biologics like bispecifics, multispecifics, and antibody-drug conjugates.
MoU Signing
On December 2, 2025, WuXi Biologics signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to expand its global CRDMO network to the Middle East.
Key Figures
The MoU was witnessed by H.E. Sheikh Faisal bin Thani bin Faisal Al-Thani, Minister of Commerce and Industry of Qatar, and signed by H.E. Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO of QFZ, and Dr. Chris Chen, CEO of WuXi Biologics.
Strategic Collaboration
This partnership will establish WuXi Biologics' first integrated CRDMO center in the Middle East, combining its one-stop CRDMO solutions and expertise in complex biologics with Qatar's vision for biopharmaceutical advancement.
Focus Areas
The collaboration aims to drive innovation and growth in Qatar's biotechnology sector, focusing on complex biologics such as bispecifics, multispecifics, and antibody-drug conjugates, while developing a robust biopharmaceutical ecosystem in the region.
